CanSino Biologics, Inc. Class H (6185) Stock Statistics & Valuation Metrics

CanSino Biologics, Inc. Class H has a market cap or net worth of HK$13.55B. The enterprise value is HK$11.10B.

CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

CanSino Biologics, Inc. Class H’s return on equity (ROE) is -0.08 and return on invested capital (ROIC) is -5.33%.

The current PE Ratio of CanSino Biologics, Inc. Class H is ―. CanSino Biologics, Inc. Class H’s PEG ratio is 0.26.

In the last 12 months, CanSino Biologics, Inc. Class H had revenue of 846.34M and earned -378.88M in profits. Earnings per share was -1.53.

In the last 12 months, operating cash flow was 58.23M and capital expenditures -328.98M, giving a free cash flow of -270.75M billion.

CanSino Biologics, Inc. Class H pays an annual dividend of HK$0.937, resulting in a dividend yield of ―

CanSino Biologics, Inc. Class H upcoming earnings date is Apr 1, 2026, TBA (Confirmed).

CanSino Biologics, Inc. Class H as a current ratio of 2.42, with Debt / Equity ratio of 38.52%

In the past 12 months, CanSino Biologics, Inc. Class H has paid 2.47M in taxes.

CanSino Biologics, Inc. Class H EV to EBITDA ratio is -57.72, with an EV/FCF ratio of -12.42.

CanSino Biologics, Inc. Class H has HK$3.27B in cash and marketable securities with HK$1.89B in debt, giving a net cash position of HK$1.38B billion.

Gross margin is 74.54%, with operating margin of -44.33%, and net profit margin of -44.77%.

The average price target for CanSino Biologics, Inc. Class H is HK$60.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy